(lp0
S'5.689 MarketWatch - Apr 13, 2013 Chimerix Inc. Watchlist CreateCMRXAlert. Open. Last Updated: Apr 17, 2017 3:23 p.m. Real time quote. $ 5.689. 0.059 1.05%.'
p1
aS"Here's Why Chimerix Inc Jumped 14.3% in April Motley Fool - May 6, 2016 What: Shares of Chimerix , a clinical-stage biopharmaceutical company, continued to crawl back to life in April as the company's stock jumped 14.3% during the month, according to data from S&amp;P Global Market Intelligence."
p2
aS'Why Chimerix Inc. Is Up Big Today Motley Fool - Jan 19, 2016 During the recent J.P. Morgan Healthcare Conference, its management team provided investors with an update on its plans for the year ahead, which included releasing more clinical data from the SUPPRESS trial in February.'
p3
aS'Chimerix: Bullish On This Biotech Selling At Cash Value Seeking Alpha - Mar 2, 2017 In the Intelligent Investor, Graham calls investing  &quot;an investment operation is one which, upon thorough analysis, promises safety of principal and an adequate return.Chimerix Announces Fourth Quarter and Full Year 2016 Financial Results - GlobeNewswire '
p4
aS'Chimerix Inc. CMRX  Wall Street Journal - Apr 5, 2013 News Chimerix Inc.CMRX. Significant News Only. 03/02/17; Press Release. Chimerix Announces Fourth Quarter and Full Year 2016 Financial Results.'
p5
aS'How Technical Indicators Have Come Out? - Chimerix, Inc. , Diamond ... Post Analyst - 22 hours ago Chimerix, Inc.  traded at an unexpectedly low level on 04/13/2017 when the stock experienced a -1.05% loss to a closing price of $5.63.Chimerix Inc  Expected to Post Earnings of -$0.37 Per Share - The Cerbat GemChimerix, Inc.  Reviewed By Analysts - The De Soto Edge'
p6
aS"Upcoming Events - Late-Stage Data From Trevena And Chimerix Seeking Alpha - Jan 27, 2017 Welcome to your weekly digest of approaching regulatory and clinical readouts. During the current quarter two Phase III trials are expected to yield data with Trevena's pain project oliceridine, which is said to be differentiated from current opioids ..."
p7
aS'Chimerix Inc.  Plunges 5.46% on April 05 Equities.com - Apr 5, 2017 Chimerix Inc.  had a rough trading day for Wednesday April 05 as shares tumbled 5.46%, or a loss of $-0.35 per share, to close at $6.06.'
p8
aS'Chimerix Appoints Randall Lanier, PhD as Chief Science Officer, and Roy W ... GlobeNewswire  - Jan 5, 2017 Prior to joining Chimerix, Dr. Ware held multiple positions in research including as a research scientist at PharmaCore, Inc.; as a consultant to Scynexis, Inc. working in chemical process development and cGMP synthesis; and leading a team of medicinal&nbsp;...'
p9
aS"Why We Backed Up Our Truck For Chimerix Seeking Alpha - Feb 2, 2016 On December 30, 2015, Steve Cohen and his Point72 collectives disclosed their purchase of 2,454,943 of Chimerix's 46.1 million shares ."
p10
a.